Jim Cramer: This Health Care Stock Has Been 'Horrendous'

Benzinga_recent_news12-05 21:19

On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ:RXRX) has been “horrendous” and he does not like to recommend horrendous stocks. On the earnings ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589889017?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/05/Jim-Cramer.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2025-12-05 21:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589889017","market":"us","top_or_hot":-1,"title":"Jim Cramer: This Health Care Stock Has Been 'Horrendous'","media":"Benzinga_recent_news","content":"<div>\n<p>On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ:RXRX) has been “horrendous” and he does not like to recommend horrendous stocks.\nOn the earnings ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jim Cramer: This Health Care Stock Has Been 'Horrendous'</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJim Cramer: This Health Care Stock Has Been 'Horrendous'\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-05 21:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ:RXRX) has been “horrendous” and he does not like to recommend horrendous stocks.\nOn the earnings ...</p>\n\n<a href=\"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4548","symbol_name":"巴美列捷福持仓","start_time":0,"source_url":"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous","article_id":"2589889017","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/05/Jim-Cramer.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/short-ideas/25/12/49228998/jim-cramer-this-health-care-stock-has-been-horrendous","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589889017","pubTimestamp":1764940740,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4548":"巴美列捷福持仓","BK4139":"生物科技","BK4611":"AI医疗","BK4539":"次新股","BK4609":"英伟达持仓股","RXRX":"Recursion Pharmaceuticals, Inc."},"translate_title":"吉姆·克莱默：这只医疗保健股“可怕”","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RXRX":1.98},"content_text":"On CNBC's “Mad Money Lightning Round,” on Thursday, Jim Cramer said Recursion Pharmaceuticals (NASDAQ:RXRX) has been “horrendous” and he does not like to recommend horrendous stocks.\nOn the earnings front, Recursion Pharmaceuticals posted weaker-than-expected results for the third quarter on Nov. 5. The company reported a quarterly loss of 36 cents per share, compared to market estimates of a loss of 31 cents per share. The company reported quarterly sales of $5.175 million, which missed the analyst consensus estimate of $16.983 million.\nRecursion also announced a CEO transition plan. Najat Khan, currently chief R&D and commercial officer, will succeed co-founder and CEO Chris Gibson, as chief executive officer and President.\nPrice Action: Recursion Pharmaceuticals shares jumped 5.6% to settle at $4.92 on Thursday.\nRecursion Pharmaceuticals is currently showing a mixed technical picture for traders. The stock is trading 12.2% above its 20-day SMA, which suggests some short-term strength, but it’s struggling below its 50-day, 100-day, and 200-day SMAs, indicating a bearish longer-term trend.\nThe RSI is at 54.50, which is neutral territory, suggesting that there's no immediate overbought or oversold pressure. This level indicates that momentum could shift either way, so traders should watch for signs of strength or weakness in the coming sessions.\nMACD is above its signal line, indicating bullish momentum, which could be a positive sign for traders looking for a potential reversal. However, this needs to be confirmed with price action, especially given the stock’s position relative to its moving averages.\nCurrently, there are no clear support or resistance levels defined, which makes it tricky for traders to anticipate price movements. If the stock approaches the recent swing high from October, it could signal a potential breakout, while a move towards the recent swing low from November might indicate further downside.\nIn April, the stock experienced a death cross, with the 50-day SMA falling below the 200-day SMA, suggesting a bearish trend. This crossover indicates that the stock may face continued selling pressure unless it can reclaim those moving averages.\nOver the past 12 months, RXRX has declined by 25.87%, reflecting a challenging longer-term trend. \nRead Next:\nPhoto: Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589889017","isCrawlerRequest":true}